FASTinov Successfully Completes First Customer Evaluation of Revolutionary Antimicrobial Susceptibility Testing Technology

• nuno
• February 28, 2023
• antimicrobial susceptibility test, evaluation, ultra-rapid ast
• 0

FASTinov Successfully Completes First Customer Evaluation of Revolutionary Antimicrobial Susceptibility Testing Technology

February 28th 2023

(Porto, Portugal) – FASTinov, the global leader in rapid antimicrobial susceptibility testing (AST), proudly announces the successful completion of its first customer evaluation at a leading hospital. This significant milestone marks a pivotal moment in the battle against sepsis, showcasing the efficacy and seamless integration of FASTinov’s cutting-edge technology into hospital workflows.

The innovative test, boasting an unparalleled Turnaround Time (TTR) of just 2 hours from positive blood cultures, holds immense promise in revolutionizing the management of bacteraemia in sepsis contexts. This breakthrough allows healthcare professionals to obtain actionable antimicrobial susceptibility results within the same shift, empowering timely and targeted treatment decisions.

Dr. Cidália Pina Vaz, Chief Scientific Officer of FASTinov, expressed her excitement about this achievement, stating,
“We are thrilled that a first hospital has evaluated our technology, and the success it has demonstrated is incredibly gratifying. This validation underscores the potential of our solution to significantly impact patient outcomes in the fight against sepsis.”

Nuno Afonso, CEO of FASTinov, emphasized the significance of this milestone, stating,
“This marks a landmark moment for FASTinov as we transition from development to real-world implementation. The successful evaluation underscores our readiness to support hospitals in delivering the fastest response possible to sepsis, providing critical insights through actionable same-shift antimicrobial susceptibility results.”

The successful integration of FASTinov’s technology into the hospital workflow represents a crucial step forward in the global battle against sepsis. By delivering rapid and precise antimicrobial susceptibility results, FASTinov is poised to revolutionize the standard of care, offering hope to patients and healthcare professionals worldwide.

About FASTinov

FASTinov is a leading innovator in rapid antimicrobial susceptibility testing, dedicated to revolutionizing patient care in sepsis contexts. With a mission to provide actionable same-shift results, FASTinov’s cutting-edge technology offers healthcare professionals unprecedented insights for targeted treatment decisions.

• For media inquiries, please contact: info@fastinov.com